A number of other research firms have also weighed in on KDMN. HC Wainwright reaffirmed a buy rating and issued a $25.00 price objective on shares of Kadmon Holdings in a research note on Monday, June 26th. Piper Jaffray Companies reaffirmed a buy rating and issued a $7.00 price objective on shares of Kadmon Holdings in a research note on Friday, July 14th. ValuEngine lowered shares of Kadmon Holdings from a sell rating to a strong sell rating in a research note on Tuesday, August 1st. Finally, Zacks Investment Research downgraded shares of Kadmon Holdings from a buy rating to a hold rating in a report on Friday, August 11th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $9.80.
Kadmon Holdings (KDMN) opened at 3.45 on Monday. The company’s market capitalization is $178.87 million. The company has a 50 day moving average of $3.42 and a 200 day moving average of $3.42. Kadmon Holdings has a 52 week low of $2.86 and a 52 week high of $7.10.
Kadmon Holdings (NASDAQ:KDMN) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.46 million. During the same period last year, the company earned ($4.40) earnings per share. The firm’s revenue was down 53.1% compared to the same quarter last year. On average, equities analysts forecast that Kadmon Holdings will post ($1.55) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Kadmon Holdings Inc (KDMN) Lowered to Sell at WBB Securities” was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://baseballnewssource.com/markets/kadmon-holdings-inc-kdmn-lowered-to-sell-at-wbb-securities/1704049.html.
In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 349,661 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $2.60, for a total value of $909,118.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 14,707 shares of company stock valued at $34,294 over the last quarter.
A number of institutional investors have recently made changes to their positions in KDMN. Perceptive Advisors LLC raised its holdings in Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock worth $18,772,000 after purchasing an additional 2,976,190 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kadmon Holdings by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after acquiring an additional 941,549 shares in the last quarter. Sabby Management LLC acquired a new position in shares of Kadmon Holdings during the second quarter valued at about $2,112,000. JPMorgan Chase & Co. increased its holdings in shares of Kadmon Holdings by 11,654.8% during the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock valued at $829,000 after acquiring an additional 226,919 shares in the last quarter. Finally, Sawtooth Solutions LLC increased its holdings in shares of Kadmon Holdings by 396.9% during the second quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock valued at $388,000 after acquiring an additional 79,593 shares in the last quarter.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with our FREE daily email newsletter.